Trial Profile
A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Prednisolone; Prednisolone; Prednisone; Prednisone
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 13 Sep 2023 Results of Dupilumab in Asia-Pacific patients with persistent asthma, presented at the 33rd Annual Congress of the European Respiratory Society
- 24 May 2023 Primary endpoint has been met, (Change in pre-bronchodilator forced expiratory volume (FEV1), as per Results presented at the 119th International Conference of the American Thoracic Society
- 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society